journal article·2024-08Open access

NAT10 Promotes Prostate Cancer Growth and Metastasis by Acetylating mRNAs of HMGA1 and KRT8

Kang‐Jing Li, Yaying Hong, Yu‐Zhong Yu, Zhiyue Xie, Dao‐Jun Lv, Chong Wang, Tao Xie, Hong Chen, Zhe‐Sheng Chen, Jianwen Zeng, Shan‐Chao Zhao

Advanced Science· Volume 11· Issue 32

Abstract

Abstract N4‐acetylcytidine (ac4C) is essential for the development and migration of tumor cells. According to earlier research, N‐acetyltransferase 10 (NAT10) can increase messenger RNAs (mRNAs) stability by catalyzing the synthesis of ac4C. However, little is known about NAT10 expression and its role in the acetylation modifications in prostate cancer (PCa). Thus, the biological function of NAT10 in PCa is investigated in this study. Compared to paraneoplastic tissues, the expression of NAT10 is significantly higher in PCa. The NAT10 expression is strongly correlated with the pathological grade, clinical stage, Gleason score, T‐stage, and N‐stage of PCa. NAT10 has the ability to advance the cell cycle and the epithelial‐mesenchymal transition (EMT), both of which raise the malignancy of tumor cells. Mechanistically, NAT10 enhance the stability of high mobility group AT‐hook 1 (HMGA1) by acetylating its mRNA, thereby promoting cell cycle progression to improve cell proliferation. In addition, NAT10 improve the stability of Keratin 8 (KRT8) by acetylating its mRNA, which promotes the progression of EMT to improve cell migration. This findings provide a potential prognostic or therapeutic target for PCa.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: RNA modifications and cancer · Cancer-related gene regulation · RNA and protein synthesis mechanisms

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Urology Nanfang Hospital Southern Medical University Guangzhou 510515 China

Department of Urology Affiliated Qingyuan Hospital Guangzhou Medical University Qingyuan People's Hospital Qingyuan 511518 China

Department of Urology The Third Affiliated Hospital of Guangzhou Medical University Guangzhou 510150 China

Luoyang Key Laboratory of Organic Functional Molecules College of Food and Drug Luoyang Normal University Luoyang Henan 471934 P. R. China

Department of Pharmaceutical Sciences College of Pharmacy and Health Sciences St. John's University Queens NY 11439 USA

Department of Urology The Fifth Affiliated Hospital Southern Medical University Guangzhou 510900 China

Department of Urology The Third Affiliated Hospital of Southern Medical University Guangzhou 510500 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · China Postdoctoral Science Foundation · Natural Science Foundation of Guangdong Province

References (53)

Show source-provided references
1. 10.3322/caac.2182010.3322/caac.21820 ↗
2. 10.3322/caac.2176310.3322/caac.21763 ↗
3. 10.1038/nature1112510.1038/nature11125 ↗
4. 10.1016/j.canlet.2015.06.02110.1016/j.canlet.2015.06.021 ↗
5. 10.1126/science.aau164610.1126/science.aau1646 ↗
6. 10.1038/s41568-020-0253-210.1038/s41568-020-0253-2 ↗
7. 10.1038/s41556-019-0319-010.1038/s41556-019-0319-0 ↗
8. 10.1002/advs.20220172410.1002/advs.202201724 ↗
9. 10.1016/j.cell.2018.10.03010.1016/j.cell.2018.10.030 ↗
10. 10.1021/acschembio.9b0036910.1021/acschembio.9b00369 ↗
11. 10.1016/j.bbrc.2003.09.23510.1016/j.bbrc.2003.09.235 ↗
12. 10.1126/science.125265110.1126/science.1252651 ↗
13. 10.1093/nar/gkaa13010.1093/nar/gkaa130 ↗
14. 10.1038/emboj.2008.15410.1038/emboj.2008.154 ↗
15. 10.1074/jbc.M114.59399610.1074/jbc.M114.593996 ↗
16. 10.3389/fendo.2022.90728610.3389/fendo.2022.907286 ↗
17. 10.1016/j.omtn.2021.06.02210.1016/j.omtn.2021.06.022 ↗
18. 10.1186/s13046-022-02551-710.1186/s13046-022-02551-7 ↗
19. 10.3389/fcell.2020.0084210.3389/fcell.2020.00842 ↗
20. 10.1002/advs.20230089810.1002/advs.202300898 ↗
21. 10.1186/s13046-022-02586-w10.1186/s13046-022-02586-w ↗
22. 10.1002/ctm2.73810.1002/ctm2.738 ↗
23. 10.3390/ijms2312657310.3390/ijms23126573 ↗
24. 10.1038/s41580-021-00404-310.1038/s41580-021-00404-3 ↗
25. 10.1038/nature0309410.1038/nature03094 ↗
26. 10.1016/j.canlet.2023.21646410.1016/j.canlet.2023.216464 ↗
27. 10.1210/er.20.4.50110.1210/er.20.4.501 ↗
28. 10.1016/S0092-8674(00)81871-110.1016/S0092-8674(00)81871-1 ↗
29. 10.1126/science.287.5459.182410.1126/science.287.5459.1824 ↗
30. 10.1101/gad.8.1.910.1101/gad.8.1.9 ↗
31. 10.1016/0092-8674(94)90257-710.1016/0092-8674(94)90257-7 ↗
32. 10.1093/emboj/16.17.533410.1093/emboj/16.17.5334 ↗
33. 10.1016/S0002-9440(10)65277-710.1016/S0002-9440(10)65277-7 ↗
34. 10.1158/1078-0432.CCR-10-281610.1158/1078-0432.CCR-10-2816 ↗
35. 10.1016/j.cell.2011.11.02510.1016/j.cell.2011.11.025 ↗
36. 10.1038/nature1489710.1038/nature14897 ↗
37. 10.1002/advs.20230171410.1002/advs.202301714 ↗
38. 10.1038/nrm375810.1038/nrm3758 ↗
39. 10.1038/nrc262010.1038/nrc2620 ↗
40. 10.1038/nrm183510.1038/nrm1835 ↗
41. 10.7150/ijbs.7295210.7150/ijbs.72952 ↗
42. 10.1007/s00018-020-03634-410.1007/s00018-020-03634-4 ↗
43. 10.1038/s41419-022-04843-410.1038/s41419-022-04843-4 ↗
44. 10.1242/jcs.114.14.256910.1242/jcs.114.14.2569 ↗
45. 10.1074/jbc.M112.42892010.1074/jbc.M112.428920 ↗
46. 10.1038/sj.bjc.660531310.1038/sj.bjc.6605313 ↗
47. 10.1016/j.canlet.2008.02.01510.1016/j.canlet.2008.02.015 ↗
48. 10.3389/fonc.2022.87514610.3389/fonc.2022.875146 ↗
49. 10.1111/cas.1312010.1111/cas.13120 ↗
50. 10.18632/oncotarget.1868310.18632/oncotarget.18683 ↗
51. 10.7150/thno.3397210.7150/thno.33972 ↗
52. 10.1186/s12943-021-01480-x10.1186/s12943-021-01480-x ↗
53. 10.1186/s12943-022-01630-910.1186/s12943-022-01630-9 ↗